Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12541355 | 0.87 | ACHE (0.34) | ACHEGDAPARP1DYRK1ACYP1A2 | |
| SCHEMBL28918223 | 0.82 | DYRK1A (0.38) | ACHEGDAPARP1DYRK1ACYP1A2 | |
| SCHEMBL12540753 | 0.76 | DYRK1A (0.34) | ACHEGDAPARP1DYRK1ACYP1A2 | |
| SCHEMBL28590000 | 0.75 | DYRK1A (0.35) | ACHEGDAPARP1DYRK1ACYP1A2 | |
| SCHEMBL30947487 | 0.75 | DYRK1A (0.40) | ACHEGDAPARP1DYRK1ACYP1A2 | |
| SCHEMBL28599648 | 0.74 | IP6K1 (0.48) | PARP1DYRK1ALMNATSHRADORA2A | |
| SCHEMBL22292592 | 0.73 | LMNA (0.41) | ACHEGDAPARP1DYRK1ACYP1A2 | |
| SCHEMBL28608978 | 0.73 | PIK3CA (0.39) | ACHEGDAPARP1DYRK1ACYP1A2 | |
| SCHEMBL28917753 | 0.72 | DYRK1A (0.32) | DYRK1ACYP1A2CYP2D6LMNATSHR | |
| SCHEMBL28585557 | 0.71 | DYRK1A (0.41) | DYRK1ACYP1A2LMNATSHRADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266903-B2 | Methods and compositions for detecting antibiotic resistant bacteria | ELITECHGROUP, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-2689031-B1 | FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE | ELITECHGROUP B V (NL) | 2016-10-19 | — | — | EP | disclosed |
| US-20160168628-A1 | METHODS AND COMPOSITIONS FOR DETECTING ANTIBIOTIC RESISTANT BACTERIA | ELITECHGROUP MDX LLC | 2016-06-16 | — | — | US | disclosed |
| EP-2971086-A1 | FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE | ELITechGroup B.V. (NL) | 2016-01-20 | — | — | EP | disclosed |
| US-9085800-B2 | Functionalized 3-alkynyl pyrazolopyrimidine analogues as universal bases and methods of use | ELITECH HOLDING B.V. (NL) | 2015-07-21 | — | — | US | disclosed |
| US-8969003-B2 | Functionalized 3-alkynyl pyrazolopyrimidine analogues as universal bases and methods of use | ELITECH HOLDING B.V. (NL) | 2015-03-03 | — | — | US | disclosed |
| WO-2014159063-A1 | FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE | ELITECH HOLDING B.V. (NL) | 2014-10-02 | — | — | WO | disclosed |
| US-20130261014-A1 | FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE | ELITECHGROUP MDX LLC | 2013-10-03 | — | — | US | disclosed |
| US-20120244535-A1 | FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE | ELITECH HOLDING B.V. | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261014-A1 | FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE | NUDT1, ADAR, DPYD | ACHE 4802/4885GDA 36/4885PARP1 273/4885 |
| US-20120244535-A1 | FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE | NUDT1, ADAR, DPYD | ACHE 4802/4885GDA 36/4885PARP1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.